Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approxim...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2010-06, Vol.24 (6), p.1121 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 1121 |
| container_title | Leukemia |
| container_volume | 24 |
| creator | Kyle, R.A Durie, B.G.M Rajkumar, S.V Landgren, O Blade, J Merlini, G Kroger, N Einsele, H Vesole, D.H Dimopoulos, M San Miguel, J Avet-Loiseau, H Hajek, R Chen, W.M Anderson, K.C Ludwig, H Sonneveld, P Pavlovsky, S Palumbo, A Richardson, P.G Barlogie, B Greipp, P Vescio, R Turesson, I Westin, J Boccadoro, M |
| description | Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein |
| doi_str_mv | 10.1038/leu.2010.60 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A229067865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A229067865</galeid><sourcerecordid>A229067865</sourcerecordid><originalsourceid>FETCH-LOGICAL-g675-e63ef2aaf91ddc10fd86b4ae6d46cfa653ae4f009618bf367ab23f6f675138073</originalsourceid><addsrcrecordid>eNptUEtLAzEQzkHBWj35BwKeW7OPZne9leKj0OKl4LFMk0mM5rEku0L_kr_SYD14kDnMfPM9BoaQm4LNC1a1dxbHecky4uyMTFjbNjPelfUFuUzpnbGibjifkK9t8EHY4MFSDc6FHoa3Iw2Kjl7igNEZj5Imo71RRoAXSN1oB9PbPBzRBgf3dL19faIi-IQ-jYn2GFOPYjCfmGg06YMqEEOIiaoQaR-DjpiSCZ6Cl1SPRqLNZ060C95krfH6h3XgQaNDP1yRcwU24fVvn5Ld48Nu9TzbvDytV8vNTPNmMUNeoSoBVFdIKQqmZMsPNSCXNRcK-KICrBVjHS_ag6p4A4eyUlxlb1G1rKmm5PYUq8Hi3ngVhgjCmST2y7LsGG_aHDIl839UuSQ6kz-ByuT9H8M3gJeCAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management</title><source>SpringerLink Journals</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kyle, R.A ; Durie, B.G.M ; Rajkumar, S.V ; Landgren, O ; Blade, J ; Merlini, G ; Kroger, N ; Einsele, H ; Vesole, D.H ; Dimopoulos, M ; San Miguel, J ; Avet-Loiseau, H ; Hajek, R ; Chen, W.M ; Anderson, K.C ; Ludwig, H ; Sonneveld, P ; Pavlovsky, S ; Palumbo, A ; Richardson, P.G ; Barlogie, B ; Greipp, P ; Vescio, R ; Turesson, I ; Westin, J ; Boccadoro, M</creator><creatorcontrib>Kyle, R.A ; Durie, B.G.M ; Rajkumar, S.V ; Landgren, O ; Blade, J ; Merlini, G ; Kroger, N ; Einsele, H ; Vesole, D.H ; Dimopoulos, M ; San Miguel, J ; Avet-Loiseau, H ; Hajek, R ; Chen, W.M ; Anderson, K.C ; Ludwig, H ; Sonneveld, P ; Pavlovsky, S ; Palumbo, A ; Richardson, P.G ; Barlogie, B ; Greipp, P ; Vescio, R ; Turesson, I ; Westin, J ; Boccadoro, M</creatorcontrib><description>Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi: 10.1038/leu.2010.60; published online 22 April 2010 Keywords: monoclonal gammopathy of undetermined significance; smoldering multiple myeloma; International Myeloma Working Group; MGUS</description><identifier>ISSN: 0887-6924</identifier><identifier>DOI: 10.1038/leu.2010.60</identifier><language>eng</language><publisher>Nature Publishing Group</publisher><subject>Care and treatment ; Distribution ; Monoclonal gammopathies ; Multiple myeloma ; Practice guidelines (Medicine) ; Risk factors</subject><ispartof>Leukemia, 2010-06, Vol.24 (6), p.1121</ispartof><rights>COPYRIGHT 2010 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kyle, R.A</creatorcontrib><creatorcontrib>Durie, B.G.M</creatorcontrib><creatorcontrib>Rajkumar, S.V</creatorcontrib><creatorcontrib>Landgren, O</creatorcontrib><creatorcontrib>Blade, J</creatorcontrib><creatorcontrib>Merlini, G</creatorcontrib><creatorcontrib>Kroger, N</creatorcontrib><creatorcontrib>Einsele, H</creatorcontrib><creatorcontrib>Vesole, D.H</creatorcontrib><creatorcontrib>Dimopoulos, M</creatorcontrib><creatorcontrib>San Miguel, J</creatorcontrib><creatorcontrib>Avet-Loiseau, H</creatorcontrib><creatorcontrib>Hajek, R</creatorcontrib><creatorcontrib>Chen, W.M</creatorcontrib><creatorcontrib>Anderson, K.C</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Sonneveld, P</creatorcontrib><creatorcontrib>Pavlovsky, S</creatorcontrib><creatorcontrib>Palumbo, A</creatorcontrib><creatorcontrib>Richardson, P.G</creatorcontrib><creatorcontrib>Barlogie, B</creatorcontrib><creatorcontrib>Greipp, P</creatorcontrib><creatorcontrib>Vescio, R</creatorcontrib><creatorcontrib>Turesson, I</creatorcontrib><creatorcontrib>Westin, J</creatorcontrib><creatorcontrib>Boccadoro, M</creatorcontrib><title>Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management</title><title>Leukemia</title><description>Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi: 10.1038/leu.2010.60; published online 22 April 2010 Keywords: monoclonal gammopathy of undetermined significance; smoldering multiple myeloma; International Myeloma Working Group; MGUS</description><subject>Care and treatment</subject><subject>Distribution</subject><subject>Monoclonal gammopathies</subject><subject>Multiple myeloma</subject><subject>Practice guidelines (Medicine)</subject><subject>Risk factors</subject><issn>0887-6924</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptUEtLAzEQzkHBWj35BwKeW7OPZne9leKj0OKl4LFMk0mM5rEku0L_kr_SYD14kDnMfPM9BoaQm4LNC1a1dxbHecky4uyMTFjbNjPelfUFuUzpnbGibjifkK9t8EHY4MFSDc6FHoa3Iw2Kjl7igNEZj5Imo71RRoAXSN1oB9PbPBzRBgf3dL19faIi-IQ-jYn2GFOPYjCfmGg06YMqEEOIiaoQaR-DjpiSCZ6Cl1SPRqLNZ060C95krfH6h3XgQaNDP1yRcwU24fVvn5Ld48Nu9TzbvDytV8vNTPNmMUNeoSoBVFdIKQqmZMsPNSCXNRcK-KICrBVjHS_ag6p4A4eyUlxlb1G1rKmm5PYUq8Hi3ngVhgjCmST2y7LsGG_aHDIl839UuSQ6kz-ByuT9H8M3gJeCAQ</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Kyle, R.A</creator><creator>Durie, B.G.M</creator><creator>Rajkumar, S.V</creator><creator>Landgren, O</creator><creator>Blade, J</creator><creator>Merlini, G</creator><creator>Kroger, N</creator><creator>Einsele, H</creator><creator>Vesole, D.H</creator><creator>Dimopoulos, M</creator><creator>San Miguel, J</creator><creator>Avet-Loiseau, H</creator><creator>Hajek, R</creator><creator>Chen, W.M</creator><creator>Anderson, K.C</creator><creator>Ludwig, H</creator><creator>Sonneveld, P</creator><creator>Pavlovsky, S</creator><creator>Palumbo, A</creator><creator>Richardson, P.G</creator><creator>Barlogie, B</creator><creator>Greipp, P</creator><creator>Vescio, R</creator><creator>Turesson, I</creator><creator>Westin, J</creator><creator>Boccadoro, M</creator><general>Nature Publishing Group</general><scope/></search><sort><creationdate>20100601</creationdate><title>Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management</title><author>Kyle, R.A ; Durie, B.G.M ; Rajkumar, S.V ; Landgren, O ; Blade, J ; Merlini, G ; Kroger, N ; Einsele, H ; Vesole, D.H ; Dimopoulos, M ; San Miguel, J ; Avet-Loiseau, H ; Hajek, R ; Chen, W.M ; Anderson, K.C ; Ludwig, H ; Sonneveld, P ; Pavlovsky, S ; Palumbo, A ; Richardson, P.G ; Barlogie, B ; Greipp, P ; Vescio, R ; Turesson, I ; Westin, J ; Boccadoro, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g675-e63ef2aaf91ddc10fd86b4ae6d46cfa653ae4f009618bf367ab23f6f675138073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Care and treatment</topic><topic>Distribution</topic><topic>Monoclonal gammopathies</topic><topic>Multiple myeloma</topic><topic>Practice guidelines (Medicine)</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kyle, R.A</creatorcontrib><creatorcontrib>Durie, B.G.M</creatorcontrib><creatorcontrib>Rajkumar, S.V</creatorcontrib><creatorcontrib>Landgren, O</creatorcontrib><creatorcontrib>Blade, J</creatorcontrib><creatorcontrib>Merlini, G</creatorcontrib><creatorcontrib>Kroger, N</creatorcontrib><creatorcontrib>Einsele, H</creatorcontrib><creatorcontrib>Vesole, D.H</creatorcontrib><creatorcontrib>Dimopoulos, M</creatorcontrib><creatorcontrib>San Miguel, J</creatorcontrib><creatorcontrib>Avet-Loiseau, H</creatorcontrib><creatorcontrib>Hajek, R</creatorcontrib><creatorcontrib>Chen, W.M</creatorcontrib><creatorcontrib>Anderson, K.C</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Sonneveld, P</creatorcontrib><creatorcontrib>Pavlovsky, S</creatorcontrib><creatorcontrib>Palumbo, A</creatorcontrib><creatorcontrib>Richardson, P.G</creatorcontrib><creatorcontrib>Barlogie, B</creatorcontrib><creatorcontrib>Greipp, P</creatorcontrib><creatorcontrib>Vescio, R</creatorcontrib><creatorcontrib>Turesson, I</creatorcontrib><creatorcontrib>Westin, J</creatorcontrib><creatorcontrib>Boccadoro, M</creatorcontrib><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kyle, R.A</au><au>Durie, B.G.M</au><au>Rajkumar, S.V</au><au>Landgren, O</au><au>Blade, J</au><au>Merlini, G</au><au>Kroger, N</au><au>Einsele, H</au><au>Vesole, D.H</au><au>Dimopoulos, M</au><au>San Miguel, J</au><au>Avet-Loiseau, H</au><au>Hajek, R</au><au>Chen, W.M</au><au>Anderson, K.C</au><au>Ludwig, H</au><au>Sonneveld, P</au><au>Pavlovsky, S</au><au>Palumbo, A</au><au>Richardson, P.G</au><au>Barlogie, B</au><au>Greipp, P</au><au>Vescio, R</au><au>Turesson, I</au><au>Westin, J</au><au>Boccadoro, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management</atitle><jtitle>Leukemia</jtitle><date>2010-06-01</date><risdate>2010</risdate><volume>24</volume><issue>6</issue><spage>1121</spage><pages>1121-</pages><issn>0887-6924</issn><abstract>Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi: 10.1038/leu.2010.60; published online 22 April 2010 Keywords: monoclonal gammopathy of undetermined significance; smoldering multiple myeloma; International Myeloma Working Group; MGUS</abstract><pub>Nature Publishing Group</pub><doi>10.1038/leu.2010.60</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2010-06, Vol.24 (6), p.1121 |
| issn | 0887-6924 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A229067865 |
| source | SpringerLink Journals; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Care and treatment Distribution Monoclonal gammopathies Multiple myeloma Practice guidelines (Medicine) Risk factors |
| title | Monoclonal gammopathy of undetermined significance multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T02%3A13%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoclonal%20gammopathy%20of%20undetermined%20significance%20multiple%20myeloma:%20IMWG%20consensus%20perspectives%20risk%20factors%20for%20progression%20and%20guidelines%20for%20monitoring%20and%20management&rft.jtitle=Leukemia&rft.au=Kyle,%20R.A&rft.date=2010-06-01&rft.volume=24&rft.issue=6&rft.spage=1121&rft.pages=1121-&rft.issn=0887-6924&rft_id=info:doi/10.1038/leu.2010.60&rft_dat=%3Cgale%3EA229067865%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A229067865&rfr_iscdi=true |